COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:CSCI - Post by User

COSCIENS Biopharma Inc > New Director: Pierre Labbe

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Oct 06, 2024 9:37am

100 Views

Post# 36254990

New Director: Pierre Labbe

Osisko Gold Royalties is a $4.7 billion market cap company:

"Mr. Labb has been a director of Osisko Gold Royalties Ltd. a TSX- and NYSE-listed precious metal royalty company, since 2015, and currently serves as the Chair of its Human Resources Committee and as a member of its Audit and Risk Committee."

"Mr. Labb is currently the Executive Vice-President, Finance of Fonds QScale S.E.C.":

QScale has attracted significant investments to support its expansion:

In August 2021, the company received a $150 million investment to further develop its cloud-based data processing capabilities
6
.
Desjardins Capital invested C$60 million in July 2021 for the development of a C$867 million high-density data processing center in Lvis, Quebec
7
.